Shares of Eiger BioPharmaceuticals plummeted after Bloomberg reported the company filed for Chapter 11 bankruptcy in Dallas. Eiger listed $38.8M in assets and $53.1M in liabilities in the petition, according to Bloomberg. The company filed Chapter 11 after its board explored other financing options including searching for equity financing, according to court documents, Bloomberg says. Eiger added that it will attempt to sell assets in Chapter 11. Shares of Eiger BioPharmaceuticals are down 50% to $2.50 in morning trading.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EIGR: